Biomedical leaders hope they'll be able to find bipartisan support to stall or repeal a 2.3% excise tax on all medical devices sold in the U.S. before it comes back online on Jan. 1, 2018.
More and more medical procedures are moving to the strip mall, thanks to high-deductible insurance plans that are turning patients into penny-pinchers. Hospital systems like Edward-Elmhurst Health are reacting, hedging their bets on what have been lucrative captive practices.
As policymakers and the drug and device industry look for new ways to bring treatments for life-threatening conditions to the market sooner, providers are concerned that expedited approvals could compromise patient care.
The $2 billion acquisition of NxStage will allow Fresenius to capture market share in the home dialysis segment and capitalize on payment models that favor coordinated care, analysts said.
The bill, which now awaits the president's approval, has received broad support from medical device and pharmaceutical groups as a means to add more certainty and efficiency to the product review process.
The Dublin, Ohio-based pharmaceutical and medical products distributor saw its pharmaceutical segment profit drop 7% to $505 million as companies along the pharmaceutical supply chain have taken a financial hit resulting from the increasing scrutiny surrounding surging drug prices.
There has been a recent wave of consolidation among contract research organizations as companies look to grow their pharmaceutical services and cut costs.
Invacare is finally free to build as many wheelchairs as it pleases. The U.S. Food and Drug Administration has given the company permission to ramp up manufacturing at its Elyria, Ohio, plant.
The next big biofuel source could be the most locally sourced yet—it'll come from your own skin.
The House of Representatives passed bipartisan legislation Wednesday that reauthorizes the FDA's ability to collect user fees from drug and device makers, as policymakers look to avoid thousands of layoffs if the current agreement expires.
Payments from drug and device companies to physicians and teaching hospitals hit more than $8 billion in 2016.
Medtronic and Aetna announced a new risk-based agreement for Type 1 and Type 2 diabetes patients who transition to Medtronic's insulin injectors. The deal aims to increase accountability and lower costs by tying reimbursement to outcomes.